Skip to main content Back to Top

T-Cell-Engaging Bispecific Antibodies in Cancer: What the Non-Oncology Pharmacist Needs to Know about Acute Toxicities (CE)

May 30, 2026


ABOUT THIS PODCAST

T-cell-engaging bispecific antibodies represent a major therapeutic and scientific advancement in the treatment of several types of cancer. However, they carry a risk of some unique acute toxicities, such as cytokine release syndrome and neurologic toxicity. This podcast reviews this emerging drug class and strategies for recognition and management of their unique adverse events.


SPEAKERS

  • Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, FASHP
    Clinical Oncology Pharmacy Manager, Atrium Health Levine Cancer Institute
  • Michaela Myerson, PharmD, BCPS
    NYU Langone Health

LISTEN ON


iTunes      Google            Spotify      TuneIn      iHeart Radio


The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

ASHP Podcasts